[{"orgOrder":0,"company":"YouthBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"YB002","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"YouthBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YouthBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"YouthBio Therapeutics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by YouthBio Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : YB002 is a first-in-class gene therapy designed to safely and transiently express Yamanaka factors in the brain. It is being evaluated for the treatment of alzheimer's disease.

                          Product Name : YB002

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          September 25, 2025

                          Lead Product(s) : YB002

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank